Prices delayed by at least 15 minutes | Print
KalVista Pharmaceuticals (KALV)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
Address
55 Cambridge Parkway
Suite 901 East
Cambridge
MA
USA
02142
Telephone
+1 857 9990808
Forecast key dates
| Name | Key Date |
|---|---|
| KalVista Pharmaceuticals Inc Third Quarter Earnings Results for 2025 | 2025-03-11T00:00:00 |
| KalVista Pharmaceuticals Inc Second Quarter Earnings Results for 2025 | 2024-12-06T00:00:00 |
| KalVista Pharmaceuticals Inc Annual General Meeting for 2024 | 2024-09-26T09:30:00 |
| KalVista Pharmaceuticals Inc First Quarter Earnings Results for 2025 | 2024-09-06T00:00:00 |
| KalVista Pharmaceuticals Inc Annual Report for 2024 | 2024-07-10T00:00:00 |
| KalVista Pharmaceuticals Inc Fourth Quarter Earnings Results for 2024 | 2024-06-14T00:00:00 |
| KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference | 2024-04-10T10:15:00 |
Previous key dates
| Name | Key Date |
|---|---|
| KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference | 2024-04-10T10:15:00 |
| KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference | 2024-03-12T09:20:00 |
| KalVista Pharmaceuticals Inc Third Quarter Earnings Results for 2024 | 2024-03-11T00:00:00 |
| KalVista Pharmaceuticals Inc, annual meeting of the American Academy of Allergy Asthma and Immunology | 2024-02-25T08:30:00 |
| KalVista Pharmaceuticals Inc Second Quarter Earnings Results for 2024 | 2023-12-07T00:00:00 |
| KalVista Pharmaceuticals Inc Annual General Meeting for 2023 | 2023-09-26T09:30:00 |
| KalVista Pharmaceuticals Inc First Quarter Earnings Results for 2024 | 2023-09-07T00:00:00 |
| KalVista Pharmaceuticals Inc Annual Report for 2023 | 2023-07-10T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.